Opportunistic CT-Based Quantification of Myosteatosis: A Potent Universal Imaging Biomarker for Frailty and Mortality.
Key claim: Opportunistic CT-based quantification of myosteatosis is a potent universal imaging biomarker for frailty and mortality.
Abstract
No abstract available.
Why this matters
Opportunistic CT biomarkers matter because they are extracted from scans people already have, so the measurement cost is near zero and the sample is unselected — a different regime than any clock requiring a dedicated blood draw or questionnaire. Framing myosteatosis as a ‘universal’ frailty and mortality marker consolidates a muscle-quality signal that competes with bedside frailty instruments and with ultrasound/MRI muscle readouts on the same construct. The outstanding question remains whether reducing myosteatosis via exercise or weight change tracks mortality reduction, or whether CT attenuation is only a downstream readout of unmeasured systemic illness.